研究单位：[1]First Affiliated Hospital of Guangxi Medical University[2]Peking University People's Hospital[3]Ruijin Hospital[4]The 923th Hospital of People's Liberation Army[5]Fourth Affiliated Hospital of Guangxi Medical University[6]Liuzhou General Hospital[7]Hainan General Hospital[8]The Affiliated Hospital Of Guizhou Medical University[9]The First People's Hospital of Yunnan
The only curative therapy for thalassemia major remains the replacement of the defective erythropoiesis by allogeneic hematopoietic stem cell transplantation(allo-HSCT). We conduct a prospective multicenter study to evaluate the efficacy of allo-HSCT in the treatment of thalassemia major.
